Usefulness of Technetium-99 m-2-methoxy-isobutyl-isonitrile liver scintigraphy for evaluating disease activity of non-alcoholic fatty liver disease

Hepatology Research

Volumn 42, Issue 3, 2012, Pages 273-279

  Masuda, Kosei ^a   Ono, Masafumi ^a   Fukumoto, Mitsutaka ^a   Hirose, Akira ^a   Munekage, Kensuke ^a   Ochi, Tsunehiro ^a   Okamoto, Nobuto ^a   Akagi, Naoki ^a   Ogawa, Yasuhiro ^a   Saibara, Toshiji ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Mitochondrial dysfunction; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Technetium 99m 2 methoxy isobutyl isonitrile liver scintigraphy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EVALUATION; COMORBIDITY; CONCENTRATION (PARAMETERS); DISEASE ACTIVITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER METABOLISM; LIVER SCINTISCANNING; MALE; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 84857563162     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00923.x     Document Type: Article

References (32)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
2. Ono M, Saibara T. Clinical features of nonalcoholic steatohepatitis in Japan: evidence from the literature. J Gastroenterol 2006; 41: 725-32.
3. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-17.
4. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000.
5. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-8.
6. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-50.
7. Hamaguchi M, Kojima T, Takeda N etal. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13: 1579-84.
8. Targher G, Bertolini L, Poli F etal. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54: 3541-6.
9. Targher G, Bertolini L, Rodella S etal. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-21.
10. Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009; 50: 1403-11.
11. Targher G, Bertolini L, Padovani R etal. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006; 29: 1325-30.
12. Adams LA, Lymp JF, St Sauver J etal. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
13. Rafiq N, Bai C, Fang Y etal. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-8.
14. Söderberg C, Stål P, Askling J etal. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
15. Hendel RC, Berman DS, Di Carli MF etal. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging. Circulation 2009; 119: e561-87.
16. Jones AG, Abrams MJ, Davison A etal. Biological studies of a new class of technetium complexes: the hexakis(alkylisonitrile)technetium(I) cations. Int J Nucl Med Biol 1984; 11: 225-34.
17. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 1990; 31: 1646-53.
18. Crane P, Laliberté R, Heminway S, Thoolen M, Orlandi C. Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med 1993; 20: 20-5.
19. Matsuo S, Nakae I, Tsutamoto T, Okamoto N, Horie M. A novel clinical indicator using Tc-99m sestamibi for evaluating cardiac mitochondrial function in patients with cardiomyopathies. J Nucl Cardiol 2007; 14: 215-20.
20. Unno K, Isobe S, Izawa H etal. Relation of functional and morphological changes in mitochondria to myocardial contractile and relaxation reserves in asymptomatic to mildly symptomatic patients with hypertrophic cardiomyopathy. Eur Heart J 2009; 30: 1853-62.
21. Chang YY, Lee CH, Lan MY, Wu HS, Chang CC, Liu JS. A new noninvasive test to detect mitochondrial dysfunction of skeletal muscles in progressive supranuclear palsy. Ann N Y Acad Sci 2005; 1042: 76-81.
22. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005; 42: 928-40.
23. Caldwell SH, Swerdlow RH, Khan EM etal. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 430-4.
24. Sanyal AJ, Campbell-Sargent C, Mirshahi F etal. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
25. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
26. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
27. Merriman RB, Ferrell LD, Patti MG etal. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44: 874-80.
28. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-9.
29. Arbab AS, Koizumi K, Toyama K, Arai T, Araki T. Technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 uptake in rat myocardial cells. J Nucl Med 1998; 39: 266-71.
30. Ekstedt M, Franzen LE, Mathiesen UL etal. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
31. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Stress myocardial perfusion single-photon emission computed tomography is clinically effective and cost effective in risk stratification of patients with a high likelihood of coronary artery disease (CAD) but no known CAD. J Am Coll Cardiol 2004; 43: 200-8.
32. Yamasaki Y, Nakajima K, Kusuoka H etal. Prognostic value of gated myocardial perfusion imaging for asymptomatic patients with type 2 diabetes: the J-ACCESS 2 investigation. Diabetes Care 2010; 33: 2320-6.